NASDAQ:ARTL

Artelo Biosciences Q2 2026 Earnings Results & Report

Artelo Biosciences logo
$1.35 -0.10 (-6.97%)
Closing price 11/20/2026 03:58 PM Eastern
Extended Trading
$1.37 +0.02 (+1.26%)
As of 11/20/2026 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Artelo Biosciences beat analyst earnings expectations in its Q2 2026 results, released August 12, 2026. The company reported EPS of -$0.89 versus the -$6.48 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens
Conference Call Date
Conference Call
7:00 AM ET

Artelo Biosciences EPS Results

Actual EPS
-$0.89
Consensus EPS
-$6.48
Beat/Miss
Beat by +$5.59
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 4 quarters

Artelo Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Artelo Biosciences Q2 2026 Earnings FAQ

Artelo Biosciences (NASDAQ:ARTL) reported earnings of -$0.89 per share for Q2 2026, beating the consensus estimate of -$6.48. The report was announced on Wednesday, August 12, 2026.

Artelo Biosciences Earnings Headlines

What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
See More Artelo Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Artelo Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Artelo Biosciences and other key companies, straight to your email.

About Artelo Biosciences

Artelo Biosciences (NASDAQ:ARTL) is a clinical-stage biopharmaceutical company developing treatments that target the endocannabinoid system and related biological pathways. Its research focuses on potential therapies for conditions with significant unmet medical needs, including cancer-related symptoms and pain.

The company’s programs have included ART27.13, a cannabinoid receptor agonist being studied for cancer-related anorexia and cachexia, and ART26.12, a small-molecule inhibitor of fatty acid binding protein 5 under investigation for potential therapeutic applications. Artelo has also developed ART12.11, a cannabidiol-based cocrystal formulation.

Artelo is headquartered in the San Diego area of California. Its work is centered on drug research and development rather than the commercial sale of approved medicines.

View Artelo Biosciences Profile